ExpreS2ion Biotech Announces Pareto Securities Analyst Update on Q1 2025 Results and Clinical Trial Progress

Hørsholm, Denmark, 21 May 2025 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion" or the “Company”) is pleased to announce that that Pareto Securities has published a new analyst newsflash following the Company’s recently reported Q1 2025 financial results and clinical trial developments.

In the report, Pareto Securities reiterated their "Buy" recommendation with an unchanged price target of SEK 303 per share. Key highlights from the report include:

• ExpreS2ion’s Q1 2025 cash position stood at SEK 58 million, with expectations for sufficient cash runway into next year.

• Management reaffirmed expected timelines for the flagship ES2B-C001 breast cancer vaccine asset, targeting a potential Phase II initiation in 2027 pending successful Phase I data.

• An amendment request to the clinical trial protocol has been submitted, aiming to enable combination therapy with antibody-drug-conjugates and expand referral centre networks, anticipated to be approved in Q3 2025.

• The analyst expects this protocol amendment to potentially expedite patient recruitment significantly.

• The recent Letter of Intent with WuXi Vaccines was noted for its potential strategic and revenue-generating opportunities from next year.

The full Pareto Securities report, along with previously published analyst reports about ExpreS2ion, is available on the company’s investor website here: Analyst Reports.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB

For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com 

About ExpreS2ion
ExpreS2ion is a biotechnology company that develops innovative vaccines for a healthier world. We want to transform healthcare by developing novel vaccines, that are life-saving and improving quality of life across the world. ExpreS2ion has developed the unique human clinical Phase III-validated technology platform, ExpreS2™, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2™, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, ExpreS2ion has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.